A Single-center Phase II Study to Investigate the Immune Maintenance Therapy Pattern in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Who Have Achieved MPR After Neoadjuvant Immunotherapy Combined With Chemotherapy

In this study, doctors are looking at a special treatment for people with a type of head and neck cancer called **squamous cell carcinoma**. This cancer affects the skin and the moist linings of the mouth and throat. The study is for patients who have already received initial treatments, including **immunotherapy** (a treatment that helps the immune system fight cancer) and **chemotherapy** (a drug treatment that uses powerful chemicals to kill fast-growing cells in the body). These patients must have had a **major pathological response (MPR)**, which means the cancer shrunk significantly after treatment. The goal is to see if continuing immunotherapy helps keep the cancer away and is safe.

• The study is for adults aged 18 to 80 years old.
• Participants will be monitored for safety and effectiveness of the treatment.
• Eligibility requirements must be met, such as good bone marrow, liver, and kidney function.

Before joining, participants should understand the study requirements, such as regular hospital visits. This study hopes to improve survival in patients with advanced head and neck cancers.